Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;166(1):201-211.
doi: 10.1016/j.chest.2024.03.002. Epub 2024 Mar 5.

Atrial Arrhythmias in Patients With Pulmonary Hypertension

Affiliations
Review

Atrial Arrhythmias in Patients With Pulmonary Hypertension

Kyle O'Meara et al. Chest. 2024 Jul.

Abstract

Topic importance: Atrial arrhythmias (AA) are common in patients with pulmonary hypertension (PH) and contribute to morbidity and mortality. Given the growing PH population, understanding the pathophysiology, clinical impact, and management of AA in PH is important.

Review findings: AA occurs in PH with a 5-year incidence of 10% to 25%. AA confers a higher morbidity and mortality, and restoration of normal sinus rhythm improves survival and functionality. AA is thought to develop because of structural alterations of the right atrium caused by changes to the right ventricle (RV) due to elevated pulmonary artery pressures. AA can subsequently worsen RV function. Current guidelines do not provide comprehensive recommendations for the management of AA in PH. Robust evidence to favor a specific treatment approach is lacking. Although the role of medical rate or rhythm control, and the use of cardioversion and ablation, can be inferred from other populations, evidence is lacking in the PH population. Much remains to be determined regarding the optimal management strategy. We present here our institutional approach and discuss areas for future research.

Summary: This review highlights the epidemiology and pathophysiology of AA in patients with PH, describes the relationship between AA and RV dysfunction, and discusses current management practices. We outline our institutional approach and offer directions for future investigation.

Keywords: PAH; PH; atrial arrhythmia; atrial fibrillation; atrial flutter; pulmonary arterial hypertension; pulmonary hypertension; right ventricle; right ventricular dysfunction.

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: R. C. reports financial support was provided by Johnson & Johnson Innovative Medicine, Bayer Corporation, Merck, Gossamer Bio Inc, Third Pole, Respira, Aria CV, and Liquidia Corporation Inc. R. S. reports financial support was provided by Merck, United Therapeutics Corporation, and Johnson & Johnson Innovative Medicine. E. B. reports financial support was provided by Biosense Webster Inc. and AtriCure Inc. None declared (K. O., G. S., A. B., A. E. S., A. B.).

Similar articles

Cited by

MeSH terms